[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stock Index Futures Gain on Tech Boost Ahead of Fed Decision and Megacap Earnings

June S&P 500 E-Mini futures (ESM26) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.27% this morning, buoyed by gains in technology stocks, while investors await the Federal Reserve’s...

GOOGL : 349.94 (+0.05%)
ADS.D.DX : 150.150 (+9.20%)
BE : 287.97 (+27.21%)
SNDK : 1,064.21 (+6.17%)
F : 12.24 (-1.29%)
ESM26 : 7,196.50 (+0.40%)
MSFT : 424.46 (-1.12%)
QCOM : 156.00 (+4.00%)
STX : 643.30 (+11.10%)
V : 334.86 (+8.26%)
WDC : 412.76 (+5.57%)
AZN.LN : 13,692.000 (-1.50%)
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir ...

GSK.LN : 1,918.000 (-5.42%)
PFE : 26.26 (-0.83%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 2.9000 (-0.68%)
GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Grant funding awarded to support lupus-focused community programs across the United States

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
Legal questions swirl around FDA's new expedited drug program, including who should sign off

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations

GSK.LN : 1,918.000 (-5.42%)
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...

GSK.LN : 1,918.000 (-5.42%)
GSK : 51.40 (-5.64%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.